The U.S. cardiac resynchronization therapy market was valued at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, registering a CAGR of 4.9% from 2020 to 2027. Surge in ...

Please provide your email address to receive an email when new articles are posted on . Long-term CRT-D use was tied to improved survival and time to adverse events vs. ICD therapy in patients with ...

SILVER SPRING, MD — Women, compared with men, showed improved survival from cardiac resynchronization therapy (CRT) across a wider range of prolonged QRS durations, a key factor in guidelines-based ...

For patients with heart failure, a reduced ejection fraction, and an indication for cardiac resynchronization therapy (CRT), using His-Purkinje conduction system pacing (HPCSP) is safe and feasible ...

Please provide your email address to receive an email when new articles are posted on . Device-based therapy may be necessary for certain patients with NYHA class II/III heart failure with reduced ...

The Resynchronization–Defibrillation for Ambulatory Heart Failure Trial (RAFT) showed a greater benefit with respect to mortality at 5 years among patients who received cardiac-resynchronization ...

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the ACUITY™ X4 Quadripolar Left Ventricular (LV) leads. The FDA approval of the quadripolar leads, the ...

George H. Crossley, M.D.; Kazutaka Aonuma, M.D.; Charles Haffajee, M.D.; Morio Shoda, M.D.; Albert Meijer, M.D.; Alexander Bauer, M.D.; Alexander Bauer, M.D ...